Skip to main content
An official website of the United States government
Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

anti-HER2 bispecific antibody-drug conjugate ZW49

An antibody-drug conjugate (ADC) consisting of a bispecific monoclonal antibody (ZW25) directed against two different epitopes of the tumor-associated antigen (TAA) human epidermal growth factor receptor 2 (HER2, receptor tyrosine-protein kinase erbB-2) linked to an as of yet undisclosed cytotoxic payload, with potential antineoplastic activity. Upon intravenous administration, anti-HER2 bispecific ADC ZW49 targets and binds to HER2 expressed on tumor cells. Following receptor internalization, the cytotoxic payload is released and induces tumor cell death through an as of yet unknown mechanism of action. Additionally, binding of HER2 may inhibit HER2 activation, HER2 signaling and HER2-mediated tumor cell growth. HER2, a tyrosine kinase receptor, is overexpressed by many cancer cell types.
Check for active clinical trials using this agentView this agent in the NCI Thesaurus
Synonym:anti-HER2 bispecific ADC ZW49
Code name:ADC ZW49
ZW-49
ZW49
Search NCI's Drug Dictionary
Please enter up to 30 characters for your search